| 9.93 -0.04 (-0.4%) | 05-22 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 12.2  |
1-year : | 14.25 |
| Resists | First : | 10.44 |
Second : | 12.2 |
| Pivot price | 8.21 |
|||
| Supports | First : | 7.78 |
Second : | 6.13 |
| MAs | MA(5) : | 9.8 |
MA(20) : | 7.8 |
| MA(100) : | 7.52 |
MA(250) : | 8.04 |
|
| MACD | MACD : | 0.8 |
Signal : | 0.5 |
| %K %D | K(14,3) : | 88.6 |
D(3) : | 87.9 |
| RSI | RSI(14): 75.9 |
|||
| 52-week | High : | 10.44 | Low : | 5.65 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ FENC ] has closed below upper band by 19.7%. Bollinger Bands are 279.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 10.47 - 10.53 | 10.53 - 10.57 |
| Low: | 9.66 - 9.73 | 9.73 - 9.79 |
| Close: | 9.84 - 9.94 | 9.94 - 10.02 |
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Fri, 22 May 2026
H.C. Wainwright raises Fennec Pharmaceuticals stock price target on growing adoption By Investing.com - Investing.com Australia
Fri, 22 May 2026
New PEDMARK studies at 2026 ASCO showcased by Fennec (NASDAQ: FENC) - Stock Titan
Fri, 22 May 2026
symbol__ Stock Quote Price and Forecast - CNN
Thu, 21 May 2026
Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting - The Manila Times
Tue, 19 May 2026
FENC: PEDMARK's growth accelerates with expanded markets, global partnerships, and long-term exclusivity - TradingView
Mon, 18 May 2026
Fennec grants stock options to three new employees under 2026 Equity Inducement Plan - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 35 (M) |
| Shares Float | 17 (M) |
| Held by Insiders | 14.3 (%) |
| Held by Institutions | 54.2 (%) |
| Shares Short | 1,060 (K) |
| Shares Short P.Month | 913 (K) |
| EPS | -0.29 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.03 |
| Profit Margin | -16.5 % |
| Operating Margin | -0.8 % |
| Return on Assets (ttm) | -6 % |
| Return on Equity (ttm) | -52.7 % |
| Qtrly Rev. Growth | 72.5 % |
| Gross Profit (p.s.) | 1.35 |
| Sales Per Share | 1.46 |
| EBITDA (p.s.) | -0.16 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -6 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -34.25 |
| PEG Ratio | 1.4 |
| Price to Book value | 9.54 |
| Price to Sales | 6.76 |
| Price to Cash Flow | -59.69 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|